PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer Marleen KokWilbert ZwartRob Michalides Preclinical study 09 March 2010 Pages: 1 - 12
Loss of ICAM-1 signaling induces psoriasin (S100A7) and MUC1 in mammary epithelial cells S. PeterssonE. ShubbarC. Enerbäck Preclinical study 09 March 2010 Pages: 13 - 25
Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells Laura B. CarpinLissett R. BickfordRebekah A. Drezek Preclinical study 10 March 2010 Pages: 27 - 34
Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines Lynnette Fernández-CuestaSuresh AnagantiMagali Olivier Preclinical study 11 March 2010 Pages: 35 - 42
Biological and clinical implications of nicastrin expression in invasive breast cancer Aleksandra FilipovićJulian Hendrik GronauR. Charles Coombes Preclinical study 12 March 2010 Pages: 43 - 53
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells Hyun ChangHei-Cheul JeungHyun Cheol Chung Preclinical study 12 March 2010 Pages: 55 - 63
Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy Sylvain LadoireLaurent ArnouldFrançois Ghiringhelli Preclinical study 13 March 2010 Pages: 65 - 72
Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins Ching-Shyang ChenChia-Hwa LeeYuan-Soon Ho Preclinical study 13 March 2010 Pages: 73 - 87
Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2 Kai-xin ZhangConnie KimPaul S. Rennie Preclinical study 16 March 2010 Pages: 89 - 97
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01) Jeong Eun KimJin-Hee AhnSi-Young Kim Clinical trial 05 October 2010 Pages: 99 - 106
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer Jiyoung RheeSae-Won HanTae-You Kim Clinical trial 09 October 2010 Pages: 107 - 114
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study Nicholas RobertLea KrekowJoyce O’Shaughnessy Clinical trial 14 October 2010 Pages: 115 - 120
Pure flat epithelial atypia (DIN 1a) on core needle biopsy: study of 60 biopsies with follow-up surgical excision Vincent LavouéClaire Marie RogerJean Levêque Clinical trial 14 October 2010 Pages: 121 - 126
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients Mathias WarmRonald KatesNadia Harbeck Clinical trial 20 October 2010 Pages: 127 - 136
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer Claudine IsaacsPia HerbolsheimerRebecca Slack Clinical trial 26 October 2010 Pages: 137 - 143
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Gunter von MinckwitzMichael UntchPeter Jüni Clinical trial 03 November 2010 Pages: 145 - 156
RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects Haiming SunJing BaiSongbin Fu Epidemiology 08 May 2010 Pages: 157 - 161
Preventable breast cancer is postmenopausal Kari HemminkiAsta FörstiSeyed Mohsen Mousavi Epidemiology 08 May 2010 Pages: 163 - 167
No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families Larissa A. KordeChristine M. MuellerPhuong L. Mai Epidemiology 11 May 2010 Pages: 169 - 173
Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects Haiming SunJing BaiSongbin Fu Epidemiology 13 May 2010 Pages: 175 - 179
Associations between mammographic density and serum and dietary cholesterol Ame-Lia TamburriniChristy G. WoolcottChristine M. Friedenreich Epidemiology 13 May 2010 Pages: 181 - 189
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer Rebecca L. SedjoScott Devine Epidemiology 22 May 2010 Pages: 191 - 200
No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects Yanlei MaJianjun YangHuanlong Qin Epidemiology 23 May 2010 Pages: 201 - 205
Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk Genevieve M. MonseesPeter KraftJiali Han Epidemiology 23 May 2010 Pages: 207 - 214
The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects Yiyi SunZhihe ZangLin Sun Epidemiology 27 May 2010 Pages: 215 - 219
Centrosome-related genes, genetic variation, and risk of breast cancer J. E. OlsonX. WangF. J. Couch Epidemiology 28 May 2010 Pages: 221 - 228
No evidence of MMTV-like env sequences in specimens from the Australian Breast Cancer Family Study Daniel J. ParkMelissa C. SoutheyJohn L. Hopper Epidemiology 30 May 2010 Pages: 229 - 235
Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects Yanlei MaJianjun YangHuanlong Qin Epidemiology 04 June 2010 Pages: 237 - 241
Aromatase immunoreactivity is increased in mammographically dense regions of the breast Celine M. VachonHironobu SasanoJames N. Ingle Epidemiology 05 June 2010 Pages: 243 - 252
Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: a meta-analysis involving 34,658 subjects Su LuZhanwei WangXishan Hao Epidemiology 05 June 2010 Pages: 253 - 259
No evidence for an association of human papillomavirus and breast carcinoma Raimundo Gerônimo Silva Jr.Benedito Borges da Silva Brief Report 24 August 2010 Pages: 261 - 264
A recombination-based method to characterize human BRCA1 missense variants Lucia GuidugliChiara RuganiMaria Adelaide Caligo Brief Report 25 August 2010 Pages: 265 - 272
Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer Juan de la Haba-RodríguezÁlvaro Rodríguez-LescureMiguel Martín Brief Report 28 August 2010 Pages: 273 - 278
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy Alastair M. ThompsonAndrea JohnsonWilliam G. Newman Brief Report 01 September 2010 Pages: 279 - 287
Pharmacological interventions for fertility preservation during chemotherapy Zeev Blumenfeld Letter to the Editor 31 August 2010 Pages: 289 - 290
Lack of association between two SNPs (rs1800896 and rs1800872) in IL-10 gene promoter and breast cancer in Caucasians Yan-Feng ZouFang WangXiao-Liang Feng Letter to the Editor 24 September 2010 Pages: 291 - 293
Presence of MMTV-like env gene sequences in human breast cancer Beatriz G.-T. PogoStella M. MelanaJames F. Holland Letter to the Editor 26 September 2010 Pages: 295 - 297
Same data sources, different pooled analysis result: the ongoing uncertainty in the subgroup analysis of RAD51 135G/C polymorphism and breast cancer risk Pei-Hua LuChen LiGuo-Qing Tao Letter to the Editor 28 September 2010 Pages: 299 - 300
